BiochemProbe — Life Science Research Reagents

Tabernanthalog fumarate other

Tabernanthalog is a water-soluble, non-hallucinogenic and non-toxic ibogaine analog.

For research use only. Not for human or veterinary use.

Target EGFR
Research area Cancer
Purity >98% Stock Inquire

Description

Tabernanthalog (TBG) is a water-soluble, non-hallucinogenic and non-toxic ibogaine analog with potent 5-HT2A receptor (human and mouse) agonist and 5-HT2B receptor (human) antagonist activities, but no opioid agonist activity.TBG induces rat dendritic growth blockable by the 5-HT2A antagonist ketanserin in cultures and exhibits antidepressant-like efficacy in vivo (50 mg/kg via i.p. by mouse forced swimming or alcohol consumption, 40 mg/kg by rat heroin self-administration).

Biological activity

Tabernanthalog (TBG) is a water-soluble, non-hallucinogenic and non-toxic ibogaine analog with potent 5-HT2A receptor (human and mouse) agonist and 5-HT2B receptor (human) antagonist activities, but no opioid agonist activity.TBG induces rat dendritic growth blockable by the 5-HT2A antagonist ketanserin in cultures and exhibits antidepressant-like efficacy in vivo (50 mg/kg via i.p. by mouse forced swimming or alcohol consumption, 40 mg/kg by rat heroin self-administration).

Identifiers

SMILES
COC(C=C(N(C)CCN(C)C)C(NC(C=C)=O)=C1)=C1NC2=NC(C3=CN(C4CC4)C5=C3C=CC=C5)=CC=N2.CS(=O)(O)=O
InChIKey
WTEXJDGTVUQRQY-UHFFFAOYSA-N

Specifications

MW (average)
346.3777
Formula
C18H22N2O5
CAS No.
2483829-59-8
Physical state
Solid
Color
white to beige
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage
Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in H2O: 2 mg/mL, clear (warmed)

References

[1].Yang JC, et al. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial [published online ahead of print, 2020 Sep 9]. J Thorac Oncol. 2020;S1556-0
[2].Sullivan I, et al. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front Med (Lausanne). 2017 Jan 18;3:76.

Same target

Search EGFR

Same research area

Search Cancer